← Leaderboards
John C Yu
La Biomed Res Inst/ Harbor Ucla Med Ctr
$468,682
Attributed
$468,682
Total exposure
5
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$468,682 · 5
By mechanism
M01$293,682 · 4
R21$175,000 · 1
Top collaborators
No co-investigators on record.
Most similar at La Biomed Res Inst/ Harbor Ucla Med Ctr
Same institution · by research overlap
- Rowan T. Chlebowski$4,676,800
- Linda Chang$37,819,216
- Solomon Hamburg$238,960
- William M Roberts$331,362
- Nathan Fischel$238,960
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchHuman Therapy EvaluationDendritic CellsBrain NeoplasmsClinical Trial Phase INeoplasm /Cancer ImmunotherapyAcute Lymphocytic LeukemiaGene ExpressionNeoplasm /Cancer GeneticsNeoplasm /Cancer Relapse /RecurrencePediatric Neoplasm /CancerThioredoxinErythropoiesisScid MouseGenetic RegulationHematopoietic Growth FactorHematopoietic Stem CellsHuman DataBiological ModelsInhibinModel Design /DevelopmentTissue /Cell CultureNeoplasm /Cancer Therapy
Grant awards (11)
GROWTH FACTORS AFFECTING ERYTHROPOIESIS$0
M01 · FY2002 · RR
EFFECTS OF NEW CYTOKINES ON HEMATOPOIETIC STEM/PROGENITOR CELLS$0
M01 · FY2002 · RR
THIOREDOXIN IN ACUTE LYMPHOBLASTIC LEUKEMIA--THERAPY IMP$0
M01 · FY2002 · RR
TUMOR LYSATE PULSED DENDRITIC CELL IMMUNOTHERAPY FOR RECURRENT GLIOBL$237,978
M01 · FY2001 · RR
THIOREDOXIN IN ALL AND ITS THERAPEUTIC IMPLICATIONS$175,000
R21 · FY2000 · CA
GROWTH FACTORS AFFECTING ERYTHROPOIESIS$27,361
M01 · FY2000 · RR
EFFECTS OF NEW CYTOKINES ON HEMATOPOIETIC STEM/PROGENITOR CELLS$27,361
M01 · FY2000 · RR
TUMOR LYSATE PULSED DENDRITIC CELL IMMUNOTHERAPY FOR RECURRENT GLIOBL$982
M01 · FY2000 · RR
THIOREDOXIN IN ACUTE LYMPHOBLASTIC LEUKEMIA--THERAPY IMP$0
M01 · FY2000 · RR
TUMOR LYSATE PULSED DENDRITIC CELL IMMUNOTHERAPY FOR RECURRENT GLIOBL$0
M01 · FY2000 · RR
TUMOR LYSATE PULSED DENDRITIC CELL IMMUNOTHERAPY FOR RECURRENT GLIOBL$0
M01 · FY2000 · RR